For non-synonymous disease-causing mutation, 40.8% are described by the top 5% of all possible non-silent CMCs (22/438).
Vehicle treated group received 1%w/v CMC (1 ml/100 g, p.o) served as the control.
CMC 1 was excluded because of the high frequency of osteoarthritic cartilage loss in this location.
Hydrolytic activity detected on: (CMC) 1% (w/v) carboxymethyl cellulose agar.
The most frequent combination was arthrodesis in the wrist and arthroplasty in the CMC 1 joint.
The three water-based solutions tested were of two different grades of Carboxymethylcellulose (CMC): 0.5 wt.-% CMC-7HF, 0.8 wt.-% CMC-7MF, and 1.4 wt.-% CMC-7MF.
Solutions of poly vinyl) alcohol (PVOH) 39 KDa (P1), PVOH 197 KDa (P2), carboxymethylcellulose (CMC) 395 KDa (C1), and CMC 725 KDa (C2) were prepared.
(B) Intense uptake in the right CMC-1 joint and moderate uptake in the left CMC-1 joint on early-phase imaging (left), intense radioisotope uptake in both CMC-1 joints on late-phase imaging (right).
Figure 4 A 48-year-old female with symptomatic bilateral CMC-1 osteoarthritis.
The basal medium (MMN) was amended with CMC, 1.0% (w/v) (Caldwell et al. 2000).
(A) Plain radiographs showed moderate CMC-1 osteoarthritis on the left side.
